✦ LIBER ✦

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

✍ Scribed by Gennari, A; Bruzzi, P; Orlandini, C; Salvadori, B; Donati, S; Landucci, E; Guarneri, V; Rondini, M; Ricci, S; Conte, P

Book ID: 109997962
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 118 KB
Volume: 90
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6601634

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicentric phase II trial of gemcitabi

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

✍ Cappuzzo, F; Mazzoni, F; Gennari, A; Donati, S; Salvadori, B; Orlandini, C; Cett 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 90 KB

Adding bevacizumab to paclitaxel in the

Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer

✍ Kevin R. Fox 📂 Article 📅 2008 🏛 Current Science Inc. 🌐 English ⚖ 186 KB

Collection of circulating progenitor cel

Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer

✍ Pedrazzoli, P; Perotti, C; Da Prada, GA; Bertolini, F; Gibelli, N; Torretta, L; 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 995 KB

Epirubicin and paclitaxel with G-CSF sup

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

✍ R. I. Lalisang; F. L. G. Erdkamp; C. J. Rodenburg; C. T. A. M. Knibbeler-van Ros 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 210 KB

Concomitant versus sequential administra

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma : Results from the Gruppo Oncologico Nord Ovest Randomized Trial

✍ Pier Franco Conte; Valentina Guarneri; Paolo Bruzzi; Tiziana Prochilo; Barbara S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The authors performed a randomized trial comprising patients with metastatic breast carcinoma (MBC). They used a noninferiority design to evaluate whether the results of sequential administration of epirubicin and paclitaxel were not markedly worse than the concomitant ad

Paclitaxel combined with ifosfamide in a

Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance

✍ Yong Wha Moon; Joo Hyuk Sohn; Hye Jin Choi; Hyun Chang; Byeong-Woo Park; Seung I 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB